|Bid||2.7800 x 2900|
|Ask||3.6600 x 4000|
|Day's range||2.6000 - 2.8600|
|52-week range||2.3550 - 13.1800|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||N/A|
|Earnings date||09 Mar 2022 - 14 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.20|
LEXINGTON, Mass., May 23, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.
LEXINGTON, Mass., May 18, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today reported that a post-hoc analysis using computer automated grading of digital photography from the completed Phase 3 TRANQUILITY dry eye chamber trial demonstrated statistical significance (p=0.020) in favor of reproxalap over vehicle for the primary endpoint of reduction of ocular redness. As previously announced, the Phase 3 TRANQUILITY trial failed to meet the primary endpoint of ocular redness as assess
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics first quarter 2022 financial results conference call. With me today are Dr. Todd Brady, president and chief executive officer, and Bruce Greenberg, incoming Interim CFO. This morning, we issued a press release reporting our financial results for the quarter ended March 31, 2022.